BioSpace News Archive

Dynavax Technologies Corporation (“Dynavax”) (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company’s Board of Directors, effective May 7, 2021.

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for review by the FDA, with a PDUFA target action date of December 17, 2021. First quarter CAPLYTA total prescriptions (TRx) increased 23% versus the previous quarter.

Wesana Health Holdings Inc., formerly Debut Diamonds Inc., is pleased to announce that its shares will commence trading on the Canadian Securities Exchange , Monday, May 10, 2021 under the ticker symbol “WESA.”

- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids - Virtual investor and analyst event to be held in July 2021

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that HyBryte™ (hypericin) was awarded an “Innovation Passport” for the treatment of early stage cutaneous T-cell lymphoma (CTCL)

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced LAKUMED hospitals has entered into an agreement to lease and utilize a Senhance® Surgical System.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.

MedShape, Inc., recently acquired by DJO® as well as the orthopedic industry leader in promoting active, adaptive healing technologies, and CurveBeam, the leader in weight-bearing CT (WBCT) imaging, jointly announced today the initiation of a new prospective clinical study with the Orthopaedic Foot & Ankle Center (Dublin, OH).

Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that Catalyst Clinical Research will enter into a partnership with Calyx to leverage Calyx’s Medical Imaging solution for their customers’ oncology trials.